Phase II North Central Cancer Treatment Group study of 2- chlorodeoxyadenosine in patients with recurrent glioma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 2, 1999, Pages 168-171

  Rajkumar, S Vincent ^a   Burch, Patrick A ^a   Nair, Suresh ^b   Dinapoli, Robert P ^a   Scheithauer, Bernd ^a   O'Fallon, Judith R ^a   Etzell, Paul S ^c   Leitch, John M ^c   Morton, Roscoe F ^d   Marks, Randolph S ^a  

^a MAYO CLINIC   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c MeritCare Hospital   (United States)

^d Iowa Oncology Research Association CCOP   (United States)

Author keywords

2 Chlorodeoxyadenosine; Brain tumors; Chemotherapy; Clinical trial; Recurrent gliomas

Indexed keywords

CLADRIBINE; NITROSOUREA; PURINE DERIVATIVE;

ADULT; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLIOMA; HUMAN; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLADRIBINE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 17144467877     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199904000-00012     Document Type: Article

References (17)

1. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
2. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS. Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with longterm follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. J Natl Cancer Inst Monogr 1988;6:279-84.
3. Ostertag CB, Kreth FW. Iodine-125 interstitial irradiation for cerebral gliomas. Acta Neurochirur (Wien) 1992;119:53-61.
4. Coffey RJ, Lunsford LD, Flickinger JC. The role of radiosurgery in the treatment of malignant brain tumors. Neurosurg Clin N Am 1992;3:231-44.
5. Buckner JC, Brown LD, Cascino TL, et al. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neurooncol 1990;9:249-54.
6. Buckner JC, Brown LD, Kugler JW, et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 1995;82:430-5.
7. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Hematol Cell Ther 1996;38:593-101.
8. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992;327: 1056-61.
9. Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994;1:121-5.
10. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-21.
11. Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992;10:364-70.
12. Saven A, Kawasaki H, Carrera CJ, et al. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol 1993;11:671-8.
13. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993;81:597-601.
14. Madani S, Baillon J, Fries J, et al. Pyrimidine pathways enzymes in human tumors of brain and associated tissues: potentialities for the therapeutic use of N-(phosphonacetyl-L-aspartate and 1-beta-D-arabinofuranosylcytosine. Eur J Cancer Clin Oncol 1987;23: 1485-90.
15. Grieb P, Skierski J, Jagielski J, Ryba M, Mossakowski MJ. DNA protein flow cytometry of dissociated cultures of human anaplastic gliomas. Pattern of proliferation and differentiation, and the effect of a new cytostatic drug cladribine (2-CdA). Folia Neuropathol 1995;33:145-52.
16. Marks RS, Richardson RL, Reid JM, Bagniewski PG, Ames MM. A Phase I and pharmacologic study of 2-chlorodeoxyadenosine in patients with advanced solid tumors [abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:155.
17. Hande KR, Garrow GC. Purine antimetabolites. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia: Lippincott-Raven, 1996: 235-52.